Clear Eyes Max Redness Relief (naphazoline HCl/glycerin)
Ophthalmic Decongestants Ophthalmic (EYE) Drops
Last reviewed · Source: First Databank (FDB) drug data
Overview
Naphazoline hydrochloride, an imidazoline-derivative sympathomimetic amine, is a vasoconstrictor.
USES: Naphazoline is a decongestant used to relieve redness, puffiness, and itchy/watering eyes due to colds, allergies, or eye irritations (smog, swimming, or wearing contact lenses). It is known as a sympathomimetic (alpha receptor agonist) that works in the eye to decrease congestion. Some brands of naphazoline eye drops also contain other ingredients.
Lubricants (such as glycerin, hypromellose, or polyethylene glycol 300) help protect the eyes from more irritation. Zinc sulfate, an astringent, helps reduce redness and irritation.
Generic name: naphazoline HCl/glycerin
Pronunciation: (nah-FAZZ-oh-leen)
Drug class: Ophthalmic Decongestants
Therapeutic class: Ophthalmic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Clear Eyes Max Redness Relief
Indications
The following indications are listed for Clear Eyes Max Redness Relief:
- Dry Eye
- Ocular Irritation
- Ocular Redness
Also known as: Eye Dryness, Eye Redness, Ocular Erythema, Ophthalmic Irritation, Xerophthalmia.
Dosing
No dosing information is available for this tab.
Ophthalmic solutions of naphazoline hydrochloride are applied topically to the conjunctiva. Care must be taken to avoid contamination of the dropper tip. Some manufacturers recommend that contact lenses be removed before administration of ophthalmic solutions containing naphazoline.
Naphazoline hydrochloride nasal solutions are applied topically to the nasal mucosa. To minimize the risk of spreading infection, containers should not be used by more than one person.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Concurrent use of maprotiline or tricyclic antidepressants with naphazoline hydrochloride may potentiate the pressor effects of naphazoline.
Patients being treated with monoamine oxidase (MAO) inhibitors may experience a severe hypertensive reaction if administered with a sympathomimetic drug. Although this reaction has not specifically been reported with naphazoline, the possibility of such an interaction should be considered.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Angle-closure glaucoma
There are no severe contraindications for this drug.
- Diabetes mellitus
- Hypertension
- Hyperthyroidism
- Ocular infection
- Ocular injury
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Dizziness
- Hyperhidrosis
- Hypertension
- Ocular hypertension
- Punctate keratitis
Less Frequent
- Blurred vision
- Mydriasis
- Ocular irritation
Rare or Very Rare
- Drowsy
- General weakness
- Headache disorder
- Hyperglycemia
- Nausea
- Nervousness
- Photophobia
Precautions
No enhanced messaging available.
No enhanced messaging available.
Animal studies have not been conducted with naphazoline hydrochloride, and it is not known whether the drug can cause fetal harm when administered to a pregnant woman. Therefore, naphazoline hydrochloride should be used during pregnancy only when clearly needed.
It is not known whether naphazoline hydrochloride is distributed into milk. Because many drugs are distributed into milk, caution should be exercised when this drug is administered to a breast-feeding woman.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Dry eye | ||
| H04.12 | ICD10CM | Dry eye syndrome |
| H04.121 | ICD10CM | Dry eye syndrome of right lacrimal gland |
| H04.122 | ICD10CM | Dry eye syndrome of left lacrimal gland |
| H04.123 | ICD10CM | Dry eye syndrome of bilateral lacrimal glands |
| H04.129 | ICD10CM | Dry eye syndrome of unspecified lacrimal gland |
| H11.14 | ICD10CM | Conjunctival xerosis, unspecified |
| H11.141 | ICD10CM | Conjunctival xerosis, unspecified, right eye |
| H11.142 | ICD10CM | Conjunctival xerosis, unspecified, left eye |
| H11.143 | ICD10CM | Conjunctival xerosis, unspecified, bilateral |
| H11.149 | ICD10CM | Conjunctival xerosis, unspecified, unspecified eye |
| H16.221 | ICD10CM | Keratoconjunctivitis sicca, not specified as sjogren's, right eye |
| H16.222 | ICD10CM | Keratoconjunctivitis sicca, not specified as sjogren's, left eye |
| H16.223 | ICD10CM | Keratoconjunctivitis sicca, not specified as sjogren's, bilateral |
| H16.229 | ICD10CM | Keratoconjunctivitis sicca, not specified as sjogren's, unspecified eye |
| Ocular irritation | ||
| H57.8 | ICD10CM | Other specified disorders of eye and adnexa |
| H57.89 | ICD10CM | Other specified disorders of eye and adnexa |
| Ocular redness | ||
| H57.8 | ICD10CM | Other specified disorders of eye and adnexa |
| H57.89 | ICD10CM | Other specified disorders of eye and adnexa |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.